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ReversionIt is unresolved whether recently transmitted human immunodeﬁciency viruses (HIV) have genetic features
that speciﬁcally favour their transmissibility. To identify potential “transmission signatures”, we compared
20 full-length HIV-1 subtype C genomes from primary infections, with 66 sampled from ethnically and
geographically matched individuals with chronic infections. Controlling for recombination and phylogenetic
relatedness, we identiﬁed 39 sites at which amino acid frequency spectra differed signiﬁcantly between
groups. These sites were predominantly located within Env, Pol and Gag (14/39, 9/39 and 6/39 respectively)
and were signiﬁcantly clustered (33/39) within known immunoreactive peptides. Within 6 months of
infection, we detected reversion-to-consensus mutations at 14 sites and potential CTL escape mutations at
seven. Here we provide evidence that frequent reversion mutations probably allows the virus to recover
replicative ﬁtness which, together with immune escape driven by the HLA alleles of the new hosts,
differentiate sequences from chronic infections from those sampled shortly after transmission.
© 2009 Elsevier Inc. All rights reserved.Introduction
It is well established that HIV populations experience extreme
bottlenecks during sexual transmission (Derdeyn et al., 2004; Wolfs et
al., 1992) with approximately 80% to 90% of infections being a conse-
quenceof a single transmitted variant (Abrahamset al., 2009;Haalandet
al., 2009; Keele et al., 2008). The strongest evidence that “transmission
sieves” have been a major factor in HIV evolution is that, relative to
viruses sampled during chronic infections, recently transmitted HIV-1
subtypeCgenetic variants are in generalmore sensitive toneutralization
and tend to have both shorter V1–V2 and V1–V4 loops and fewer
glycosylation sites (Derdeynet al., 2004; Li et al., 2006;Ronget al., 2007).
Differences in sites under selection have also been identiﬁed between
the envelope glycoproteins (gp41) of viruses from the primary and
chronic infection phases suggesting the existence of different selective
pressures during these different infectionphases (Bandawe et al., 2008).
However, outside of studies on env, there is limited information on
features which distinguish recently transmitted viruses from those
found in chronic infections. Viruses from chronic infections have usuallyases and Molecular Medicine,
es, University of Cape Town,
.
illiamson).
ll rights reserved.undergone strong cytotoxic T lymphocyte (CTL) driven selection pres-
sures and are therefore expected to have accumulated immune escape
mutations. These CTL escape mutations, while highly adaptive within
the context of immune environmentswhere hosts have the appropriate
HLAalleles (Brummeet al., 2007, 2008;Kelleher et al., 2001;Rousseauet
al., 2008), can also seriouslydiminishviral replicativeﬁtness (Allen et al.,
2005; Brockman et al., 2007; Liu et al., 2006, 2007; Martinez-Picado et
al., 2006; Miura et al., 2009). Although there is some evidence from
mother to child transmission pair studies that ﬁtter virus variants are
selectively transmitted (Kong et al., 2008), other studies have shown
that genetic variants that carry attenuating CTL escape mutations are
also transmitted (Chopera et al., 2008; Goepfert et al., 2008).
Following transmission, viruses generally accumulate both
immune evasion mutations and reversion mutations that recoup
replicative ﬁtness losses experienced due to deleterious escape
mutations accrued in previous hosts (Brumme et al., 2008; Leslie
et al., 2004; Liu et al., 2007; Matthews et al., 2008; Rousseau et al.,
2008). The rate at which such reversionmutations occur is most likely
dependant on the magnitude of their effects on replicative ﬁtness
(Brumme et al., 2008; Matthews et al., 2008). The clinical importance
of viruses carrying attenuating CTL escape mutations is that the
recipients of such viruses will, in some cases at least, have lower set-
point viral loads, higher CD4 counts and possibly better survival
prospects (Chopera et al., 2008; Goepfert et al., 2008).
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during the earliest stages of infection. Identifying the speciﬁc genetic
features that might predispose particular HIV variants to being more
transmissible than others and understanding the evolutionary
processes at play during the early evolution of successfully transmitted
variants are therefore both important for deﬁning potential targets for
vaccine induced immunity. As events during acuteHIV-1 infections are
thought to have a disproportionately large inﬂuence on both long-
term disease outcomes (deWolf et al., 1997 ; Lavreys et al., 2006) and
global HIV evolution in general (Rambaut et al., 2004), understanding
the transmission bottleneck and the subsequent evolution of success-
fully transmitted variants are probably key to identifying and
understanding the viral and host determinants of HIV pathogenesis.
To identify genetic features that are characteristic of recently
transmitted viruses, we developed a phylogeny and recombination
aware method to compare amino acid mutation spectra between
groups of sequences. We used this approach to identify amino acid
sites that differentiated between full-length HIV-1 subtype C genomes
sampled during primary and chronic infections. We then examined
longitudinally sampled sequences to infer the processes that might
underlie the amino acid frequency differences observed in viruses
from the different infection phases.
Results
Classiﬁcation of infection stages
A cohort of 20 women experiencing primary HIV-1 infections was
recruited as part of the CAPRISA 002 acute infection study (van
Loggerenberg et al., 2008) (Table 1). These women were estimated to
have been infected for a median of 39 days (range 22 to 62 days) at
enrolment. Most participants had high viremia with a median viral load
of 110900copies perml (range from610 to621000 copies/ml; Table 1).
Characterization of full-length HIV-1 genomes
Full-length genomes were ampliﬁed and genetic homogeneity in
V1V2 of the template, indicative of ampliﬁcation from a single genome,
was conﬁrmed for 13 out of 20 amplicons. Heterogeneity was identiﬁedTable 1
Summary of participants' clinical markers, laboratory staging and full-length genome temp
Participants Sample date
(month-day-year)
Days
post-infectiona
Viral l
(copie
CAP8 05-17-2005 23 37300
CAP30 10-27-2004 35 1020
CAP45 05-11-2005 35 23600
CAP61 12-20-2004 57 61
CAP63 01-26-2005 34 20200
CAP65 09-06-2005 42 9080
CAP84 02-28-2005 22 914
CAP85 06-22-2005 23 62100
CAP88 02-17-2005 36 2940
CAP174 10-04-2005 28 47400
CAP206 07-12-2005 41 36800
CAP210 05-25-2005 36 12700
CAP228 05-18-2005 53 236
CAP229 07-19-2005 48 12600
CAP239 08-10-2005 36 9580
CAP244 05-23-2005 58 1920
CAP248 05-24-2005 62 5500
CAP255 06-21-2005 54 19600
CAP256 09-05-2005 42 5650
CAP257 09-12-2005 49 27600
ND=not done
a Infection date was estimated as the midpoint between the last negative and ﬁrst positiv
b Fiebig et al. (2003).
c No. bands on heteroduplex tracking assay gel.
d Determined on samples from a week before.in eachof the remaining seven samples (Table1). Ampliconswere cloned
and sequenced from each of the 20 study participants. All 20 of the full-
length genome sequences clearly belonged to HIV-1 subtype C and none
were detectably inter-subtype recombinants (Supplementary Fig. 1).
To identify polymorphisms associated with recently transmitted
viruses, we compiled from public databases a data set of subtype C
chronic sequences which were closely matched to our acute infection
data set for geographical origin, host population and mode of transmis-
sion. As we were interested in identifying genetic features that differed
between viruses sampled during primary and chronic infections, it was
necessary to ensure that there were no obvious sampling biases. The
mean genetic distances between the env genes of viruses within each
data set was similar: 11.5% (range 8.2%–14.8%) in the primary infection
data set compared to 10.9% (range 6%–15.1%) in the chronic infection
data set. In addition, therewasno obvious evidence of close epidemiolo-
gical linkage as the sequences were generally dispersed throughout a
subtype C phylogenetic tree containing viruses sampled world wide
(Supplementary Fig. 1). A comparison of the 86 sequences used in this
study showed limited structure in the phylogenetic tree (Fig. 1) with
only seven lineages displaying bootstrap support above 75%. Of these
seven lineages, six consisted of only two sequences each. Most lineages
contained a mixture of acute and chronic sequences. Thus, despite a
common geographic origin, there was no obvious evidence of close
genetic and phylogenetic relationships within or between primary and
chronic sequences.
Envelope glycoprotein variable loop length and N-linked glycosylation
Previous studies have shown statistically signiﬁcant differences in
both the lengths of variable loops and the numbers of N-linked
glycosylation (PNGs) sites found in the envelope glycoproteins of
viruses sampled during primary and chronic infections (Derdeyn et al.,
2004; Li et al., 2006). Consistent with these studies, we found
signiﬁcantly fewer PNGs in the V1V2 loop regions of the viral Env
sequences sampled during primary infections (p=0.025) (Fig. 2a). We
did not, however, ﬁnd any signiﬁcant differences between the two data
sets with respect to either the number of PNGs across the entire V1V4
region (median of 20 for both primary and chronic) or in the lengths of
the V1V2 (median of 67 and 68 amino acids in the primary and chroniclate diversity.
oad
s/ml)
CD4 count
(cells/μl)
Laboratory
stageb
Sequence template
diversity (V1V2)c
0 360 V 1
0 989 V 1
0 974 V ND
0 389 VI 1
0 584 Vd 2
0 243 VI 2
0 636 V 2
0 419 V 2
0 963 VI 1
0 353 VI 1
0 365 VI 1
0 461 V 1
0 851 VId 1
0 558 ND 1
0 845 V 2
0 557 VI 1
0 420 V 1
0 693 VI 1
0 689 VI 1
0 450 V 2
e antibody test or as 14 days if the sample was PCR positive, antibody-negative sample.
Fig. 1.Maximum Likelihood tree of env gene sequences from primary (n=20) and chronic (n=66) infection HIV-1 subtype C strains. The HXB2 subtype B strainwas used as root and
100 bootstrap replicates were done. Primary infection strains are indicated by squares and chronic strains as unlabelled tips. Subclusters indicated with thicker branches and brackets
had bootstrap values ≥85%. Scale bar=0.05.
215F.K. Treurnicht et al. / Virology 396 (2010) 213–225data sets, respectively) and V1V4 regions (median of 280.5 and 280
amino acids in the primary and chronic data sets, respectively).
Site-speciﬁc differences in amino acid frequencies between the primary
and chronic infection data sets
We used a phylogenetic approach to test for more subtle
differences between the primary and chronic infection data sets.Our method accounts for detectable signals of recombination and
controls for founder effects in the underlying evolution of these
sequences (Bhattacharya et al., 2007; Schefﬂer et al., 2006). The
method infers the amino acid states of ancestral viruses and evaluates
the difference in the mutational patterns between two groups of
sequences at each site along a protein sequence alignment (see
Materials and methods for details). Intra-subtype recombination
breakpoints were identiﬁed in gag, pol, env and nef genes. However,
Fig. 2. (a) Number of potential N-linked glycosylation sites (PNGs) in the V1–V2 variable domains of gp120 from HIV-1 subtype C strains from primary and chronic infection. (b)
Amino acid positions that displayed a signiﬁcant difference between primary and chronic infection subtype C sequences are showed graphically across the HIV-1 proteome
(pb 0.025).
216 F.K. Treurnicht et al. / Virology 396 (2010) 213–225no recombination breakpoints were found in vif, vpr, vpu and tat using
the GARD method (Pond et al., 2006; http://www.datamonkey.org).
Amino acid frequency spectra in the primary and chronic
infection data sets differed most notably at 39 amino acid sites.
These 39 sites were identiﬁed using a phylogenetically corrected
test with a multiple testing uncorrected one-tailed p-value cut-off
of 0.025. We used a permutation test to investigate the impact of
multiple hypothesis testing on our results. We permuted the sample
labels (i.e. primary versus chronic infection) randomly 1000 times
and counted the number of sites in each permuted data set that
differed signiﬁcantly (pb 0.025) between the permuted primary and
chronic groups. While in the observed (unpermuted) data, there
were 39 sites with a p-value below 0.025, among the 1000
permuted samples, the mean number of sites with a p-value
below 0.025 was 9.3 and there were no permuted data sets with as
many as 39 sites with associated p-values less than 0.025. This
provided evidence that the 39 sites we identiﬁed were signiﬁcantly
enriched for sites displaying genuine allele frequency differences
between our chronic and acute infection data sets. Speciﬁcally, we
estimated that the false discovery rate among the 39 identiﬁed sites
was approximately 24% (9.4/39 sites are false-positives).
Fourteen of the 39 sites were within Env, nine in Pol, six in Gag,
four in Nef, three in Vif, two in Vpr and one in Vpu (Fig. 2b). We then
investigated each site in detail to identify possible biological processes
responsible for these differences.
Sites differentiating the primary and chronic infection data sets have
higher entropy in the primary infection data set
To better explore the nature of the changes in amino acid
mutational spectra between the primary and chronic infection data
sets, we examined the relative entropies of the 39 identiﬁed sites (Fig.
3a). On average, the site-speciﬁc entropy was higher in the primary
infection data set (median=0.518) than it was in the chronic
infection data set (median=0.263, pb0.0001, two-tailed Wilcoxon
rank-sum test) (Fig. 3b). Based on analysis of HIV-1 protein sequences
sampled from public databases, Bansal et al. (2005) deﬁned high
entropy sites as those with an entropy score greater than 0.25 and low
entropy sites as those with an entropy score less than 0.15. Whereas
in the primary infection data set, all 25/39 sites had high entropy, inthe chronic infection data set only 12 had high entropy. Seventeen
sites with entropies from 0.325 to 0.588 in the primary infection data
set were either fully conserved or highly conserved, in the chronic
infection data set (Fig. 3c).
Sites with differential amino acid frequency spectra are signiﬁcantly
clustered within known CTL epitopes
It has been suggested that there is typically higher sequence
entropy at amino acid positions where escape mutations occur (Liu et
al., 2007) and that CTL responses during early infections mostly target
peptides with high degrees of entropy (Bansal et al., 2005). To
investigate whether the sites identiﬁed by our analysis were
associated with CTL responses, we checked the sites against the
genomic positions of peptides that were immunoreactive in Elispot
assays (http://www.hiv.lanl.gov/content/immunology/hlatem/
study4/index.html; Gray et al., 2009; Kiepiela et al., 2007; Matthews
et al., 2008). We found that 33 of the 39 sites were located within
immunoreactive peptides (Table 2). Immunoreactivity has been
mapped to approximately 48% of the HIV-1 subtype C proteome.
We found that the 39 sites clustered more frequently within these
immunoreactive regions than is expected by chance (p= 0.006). This
implied that polymorphisms at the sites differentiating the primary
and chronic infection data sets are most likely associated with CTL
immune pressures.
Longitudinal monitoring of evolution at amino acid sites which differed
between primary and chronic phases of infection
To more directly determine the nature of discordant amino acid
mutation spectra in our primary and chronic infection data sets, we
obtained longitudinal samples from 18 of the 20 study participants at
between 3 and 6 months after our initial samples were taken. We
were speciﬁcally interested in determining whether increased
entropy at the sites identiﬁed in our analysis was due to (i) viruses
sampled in primary infections carrying transient immune evasion
mutations that they had carried over from former hosts (reversion),
(ii) viruses accumulating novel immune evasion mutations in
response to changes in the immune environment following trans-
mission (escape) or (iii) a combination of both (i) and (ii).
Fig. 3. A comparison of the 39 positions identiﬁed as signiﬁcant changes (pb 0.025), in amino acid spectra between sequences from primary and chronic infection showing (a) amino
acid variety and relative frequency in primary and chronic infection, (b) difference in median entropy (pb 0.05) and (c) site-speciﬁc entropy at each position.
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substitutions within epitopes restricted by patient HLA alleles (or in
immediately adjacent amino acids) where changes were from amino
acids found in ≥50% in the population (i.e. consensus or wild-type
states) to amino acids found in b50% of the population (i.e. mutant
states; Allen et al., 2005; Liu et al., 2006; Li et al., 2007). Conversely, we
deﬁned probable reversion mutations as being amino acid substitu-
tions within known CTL epitopes that were not targeted by a patients
HLA alleles in which low-frequency amino acids were replaced with
high-frequency ones such as those corresponding with the subtype
consensus sequence (Allen et al., 2005; Liu et al., 2006; Li et al., 2007).
Amino acid changes were seen in 13 participants at 20 sites, of
which four sties were associated with both escape and reversion(Tables 3 and 4). Evolution from low- to high-frequency amino acids
(putative reversion) occurred at 14 sites and evolution to low-
frequency amino acids (putative CTL escape) were seen at seven sites.
At three sites we saw escape followed by reversion to the original
wild-type amino acid within 6 months (transient escape) post-
infection. In total, eight putative escape events were identiﬁed at
seven sites (Vif 78, Env 162, Env 352 and Nef 65) in six individuals
with one individual (CAP256) showing escape at three sites (Gag 371,
Pol 113 and Vif 78). Seven sites associated with escape evolved from
high-frequency (median frequency of 0.775) to low-frequency
(median frequency of 0.168) amino acids. At position 65 in Nef, a
change from the consensus E (frequency of 0.865) to a D is associated
with CTL escape in HLA-B⁎45/B⁎4501-positive individuals (Rousseau
Table 2
Amino acid positions were the frequency of gain and loss of speciﬁc amino acids at terminal branches differ signiﬁcantly between HIV-1 subtype C strains from primary and chronic
infection.
Protein Amino acid
position (HXB2)a
p-value Subtype C CTL reactive peptide sequence
(site in boldface and underlined)b
Known HLA restrictionb
Gag p17 69 0.0037373 EGCKQIMKQLQPALQTGT, QLQPALQTGTEELRSLY B⁎0801, B⁎4006, A2, A⁎0101, B57
Gag p17 72 0.0103261 QLQPALQTGTEELRSLY B⁎0801, B⁎4006, A2, A⁎0101, B57
Gag p17 105 0.0131367 EALDKIEEEQNK A11
Gag p24 138 0.0097975 GKVSQNY/PIVQNLQGQMV B13, A68, A⁎6802, A⁎2402
Gag p24 228 0.0163842 PVAPGQMREPRG B35, B13
Gag p2 371 0.0192564 EAMSQANSVNIM A2, A⁎0201, A2 supertype, B⁎4002, B⁎4501
Pol protease 113 0.0103261 GGIGGFIKVRQYDQIL A2, B13, Cw6
Pol protease 128 0.0015348 QIPIEICGKKAIGTVLV, GKKAIGTVLVGPTPVNII B⁎1503, B57, B58, B63
Pol protease 131 0.0103261 GKKAIGTVLVGPTPVNII B⁎1503, B57, B58. B63, A⁎0201
Pol RT 276 0.0165847 DAYFSVPLDEGFRKYTAF B⁎5702, B⁎5703, B35, B⁎3501, A11
Pol RT 447 0.0140015 AKALTDIVPLTEEA B⁎0702, B⁎1501, B⁎3501, B⁎5101, B⁎5301,
B35, B51, B7
Pol integrase 726 0.0193219 KAQEEHEKYHSNWR B⁎4403
Pol integrase 756 0.0103261 EIVASCDKCQLKGE B⁎8101
Pol integrase 813 0.0103261 PAETGQETAYYILKLAGR A⁎6802, A⁎2601, B7, B56
Pol integrase 850 0.0131367 VKAACWWAGIQQEFGIPYNPQS A2 supertype, B⁎1503
Vif 46 0.0103261 RHHYESRHPKVSSE B⁎0702, B⁎4201, B7
Vif 78 0.0158979 D/WHLGHGVSI/, LQTGERDWHLGHGVSIEW B⁎1510, B⁎5703, B35
Vif 137 0.0103261 HIVSPRCDYQAGHNKVGSLQYLAL
Vpr 68 0.0015348 AIIRILQQL/L A⁎0201, A2, A2 supertype
Vpr 81 0.0103261 GCQHSRIGILRQR
Vpu 33 0.0097975 YIEYRKLVRQR, EYRKILRQR A⁎3303
Env gp120 106 0.0103261 KNDMVDQMHEDIISLW A⁎0201, B⁎3801, A2,
Env gp120 162 0.0015348 CSFNITTELRDKKQKVYA, NCSFNISTSI Cw8, Antibody pressure
Env gp120 171 0.0007625 CSFNITTELRDKKQKVYA
Env gp120 184 0.0099403 YALFYRLDIVPLNENNSSEY
Env gp120 340 0.0192564 HCNISEAAWNKTLQQVR A11, A⁎0201
Env gp120 352 0.0200731 QQVRKKLEEHFPNKTIIF A⁎0201, A11
Env gp120 476 0.0197145 TFRPGGGDMRRNWRSELY, MRRNWRSELYKYKVVEI A⁎2601
Env gp120 477 0.0003449 TFRPGGGDMRRNWRSELY, MRRNWRSELYKYKVVEI A⁎2601
Env gp120 485 0.0103261 NWRSELYKYKVVEI
Env gp41 535 0.0191913 GSTMGAASITLTVQARQ A2
Env gp41 583 0.0015348 GIKQLQTRVLAIERYLK, RVLAIERYLKDQQLLGIW B⁎5802, B14
Env gp41 668 0.0173911 EKDLIALDKW(Q/N)NLWNWFDIT
Env gp41 687 0.0165847 WYIKIFIMIVGGLIGLR A⁎2402, A2, A⁎0201
Env gp41 708 0.0103261 AVLSVVNRVRQGYSPLS A⁎2501, A⁎3002, A30
Nef 5 0.0131367 MGGKWSKSSIV A2, A⁎2501
Nef 65 0.0000520 WLRAQEEEEEVGFPVRPQV, EVGFPVRPQVPLRPMTFK B⁎4501, B45, B7, A⁎0201, A1, B8, B35
Nef 88 0.0171700 KAAFDLSFF, GAFDLSFFL B57/B⁎5801, A⁎0205, B60, B62, A2,
Cw8, Cw⁎0802
Nef 169 0.0103261 LLHPMSQHGMDDPER B35
a Sites identiﬁed with a p-value b 0.025 are reported.
b Reactive peptides of which some contains published CTL epitopes were obtained from the Los Alamos HIV database (http://www.hiv.lanl.gov/content/immunology/hlatem/
study4/index.html, http://www.hiv.lanl.gov/content/immunology/ctl_search).
218 F.K. Treurnicht et al. / Virology 396 (2010) 213–225et al., 2008). However, in CAP63 position 65 in Nef evolved from a
low-frequency amino acid (G=0.046) to another low-frequency
amino acid (D=0.07). Although it is slightly more frequent, this new
amino acid polymorphism was classiﬁed as an escape mutation. It is
also possible that the original G polymorphism was itself also an early
escape mutation as the ﬁrst sample recorded for this patient was only
obtained approximately 34 days post-infection. Mutation to D at this
site may have simply providedmore selectively beneﬁcial escape than
was provided by the intermediate G state. In three participants, the Vif
and Nef sites were located in peptides restricted by the host HLA
(B⁎1503 and HLA-B⁎45, respectively) providing further evidence that
these sites were associated with evasion of CTL responses. The one
putative escape in Env 162 reverted to consensus at 29 weeks with
concomitant escape at an adjacent site. This oscillation of amino acids
within nine-mer CTL epitopes is commonly observed in the early
stages of escape prior to the selective expansion of viruses carrying in
most cases just the single highest ﬁtness escape mutation (Borrow et
al., 1997; Delport et al., 2008; Iversen et al., 2006). However, as this
site was located in an N-linked glycosylation motif, it is also possible
that antibody pressures played some role in its selective value.
In total, 17 potential reversion mutations were identiﬁed at 14
sites, within viruses sampled from nine of the study participants.
Longitudinally sampled viruses from CAP256 showed putativereversion at 7/14 sites with CAP174 and CAP206 each having putative
reversion mutations at two sites. Reversion mutations involved
substitutions of low-frequency amino acids (median population-
wide frequencies=0.058 at the site in question) with higher
frequency amino acids (median population-wide frequen-
cies=0.930). These potential reversion mutations were distributed
throughout the genome with six occurring in Env, three in Pol, two in
Gag and one each in Vif, Vpr and Nef (Table 4). There was no predicted
HLA association for 14 out of the 17 reversion mutations providing
further evidence that these sites were associatedwith reversion of CTL
escape mutations that had occurred in former hosts which had
different HLA alleles than the virus' current hosts. The one exception
was a probable reversion mutation located at Nef 65 within the CTL
epitope restricted by one participant's HLA-B⁎4501 allele. Impor-
tantly, escape mutations were also seen at adjacent positions (63, 64)
within this putative CTL epitope. The potential reversion at amino acid
position 162 in Env is probably associated with regain-of-function as
this site is almost invariably a threonine (T) residue (HIV-1 subtype C
population-wide frequency=0.979) and resides within a potential N-
linked glycosylation site motif in the V2 loop.
In summary, a total of 28 evolutionary events were observed in 13
participants at 20 sites of which three events were associated with
transient escape (10.7%), eight with putative escape (28.6%) and 17
Table 3
Putative escape mutations within CTL epitopes.
Site PID Weeks post-infection Putative epitopes aligned to matching test peptides Amino acid frequency change HLA restricted
Gag 371 CAP256 6 77.48N8.96 Afﬁnity=6.24
13 NNNNG B⁎1503
30
Pol 113 CAP256 6 97.68N2.09 Afﬁnity=457.37
13 RNRNK B1503
30
Pol 756 CAP45 2 98.84N0.46 No
5 DNDNG
12
Vif 78 CAP256 6 0.386→0.061 B⁎1503
13 E→A
30
Vpr 81 CAP239 5 100N0 No
11 IN INM
22
Env 352 CAP244 8 0.727→0.168 No
12 E→K
28
Nef 65 CAP85 5 0.865→0.07 B⁎4501
13 E→D
29
CAP63 5 0.046→0.07 B⁎4501
11 G→D
29
Transient escape
Vif 46 CAP45 2 96.33N0.73N96.33 Afﬁnity=137.72, A⁎2902
5 SNNNS
12
Env 162 CAP63 5 0.979→0.006→0.979 No
11 T→S→T
29
Nef 88 CAP257 7 76.28N23.21 Afﬁnity=183.39
14 SNGNS B⁎4202
30
Afﬁnity: Nielsen et al., 2007.
219F.K. Treurnicht et al. / Virology 396 (2010) 213–225with putative reversion (60.7%). Thus, the longitudinal evolutionary
changes observed at these sites weremainly associatedwith reversion
to high-frequency amino acids during primary infection with a
minority of changes potentially being associated with CTL escape.
Discussion
HIV transmission is associated with a severe virus population
bottleneck and there is some evidence that certain genotypic and
phenotypic properties of the viral envelope are selectively advantageous
during transmission (Derdeyn et al., 2004; Rong et al., 2007;Wolfs et al.,
1992). However, open questions remain as to whether this holds true
both for genome regions other than the envelope and for all HIV-1M
subtypes. To further explore this concept, we generated full-length
genomes from 20 recently HIV-1 subtype C infected individuals and
compared these sequences to those sampled during chronic infections.
Similar to Li et al. (2006) we also found fewer glycosylation sites but not
shorter variable loop lengths within the envelopes of viruses sampled
during primary infections. However, in an analysis corrected for founder
effects and recombination, we found that site-speciﬁc amino acidmutational differences across the full-length proteome are almost
exclusively associated with signals of virus adaptation to the new host
rather than with signatures obviously associated with preferential
transmission.
Our study describes full-length HIV-1 subtype C genomes sampled
from individuals during the primary phase of infection. We identiﬁed
39 sites within the proteomes of these viruses that differentiated
them from viruses sampled during chronic infections. Through
longitudinal analysis of amino acid frequency changes that occurred
during the ﬁrst 6 months of infection, together with data on host HLA
alleles, we provide evidence that approximately 28.6% of site-speciﬁc
differences in amino acid frequency spectra between primary and
chronic infection proteomes are potential immune escape mutations.
The remaining 60.7% of frequency differences between the two groups
are probably due to defunct immune evasion substitutions reverting
to consensus amino acid states following transmission. These data
provide further understanding of processes determining the genomic
and immunogenic properties of viruses during early infections which
is important if we are to understand HIV pathogenesis sufﬁciently
well to design protective vaccines against the virus.
Table 4
Putative reversion mutations.
Site PID Weeks post-infection Putative epitopes aligned to matching test peptides Amino acid frequency change Fold frequency increasea HLA restricted
Gag 69 CAP256 6 0.157→0.823 5.24 No
13 K→Q
30
Gag 228 CAP256 6 0.0024→0.981 409 No
13 I→ I→M
30
Pol 131 CAP174 4 0→1.00 B⁎5802
28 A→V
Pol 447 CAP255 8 0.0534→0.944 17.7 No
13 V→ I
Pol 850 CAP61 8 0.0139→0.981 70.6 No
11 V→ I→ I
33
CAP174 4 0.0046→0.981 213.3 No
28 T→ I
Vif 137 CAP256 6 0.0073→0.993 136 A⁎2902
13 T→T→A
30
Vpr 81 CAP206 8 0→1.00 ⁎No
15 V→ I→ I
33
Env 106 CAP239 5 0.0019→0.932 490.5 No
11 K→K→E
22
Env 162 CAP206 8 0.004→0.979 245 No
15 A→T
33
Env 352 CAP256 6 0.168→0.727 4.33 No
13 K→E
30
Env 477 CAP85 5 0.070→0.927 13.2 No
13 N→D
29
CAP256 6 0.070→0.927 13.2 No
13 N→D
30
Env 535 CAP256 6 0.063→0.852 13.5 No
13 M→M→ I
30
Env 668 CAP256 6 0.173→0.781 4.5 No
13 S→N
30
Nef 65 CAP30 5 0.070→0.865 12.4 B⁎4501
11 D→E
29
CAP84 3 0.070→0.865 12.4 No
14 D→E
19
a Fold frequency increase: the difference in frequency of an amino acid at an alignment position compared to the frequency of another amino acid at the same alignment position.
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frequency spectra between viruses sampled during primary and
chronic infections were located within peptides that have known
immunoreactivity. Most of these sites were in Env followed by Pol and
Gag containing more sites than any of the remaining proteins.
We further investigated the nature of the immune selection
operating on these sites through analysis of sequence sampled
longitudinally from the study participants. Based on changes in
amino acid frequencies relative to the global HIV database, we found
that the amino acid frequency variations in 14/39 of the identiﬁed
sites were consistent with high rates of reversion mutations being
associated with either transmission or primary infection. The
frequency spectra differences at 7/39 sites were consistent with
early escape from CTL responses during primary infection. The timing
of escape may well be crucial, as none of the individuals had IFNg
responses to subtype C-based peptide pools containing the presump-
tive immunoreactive epitopes screened using the ELISPOT assay (Gray
et al., data not shown). It is also possible, however, that these assays
may have missed responses due to mismatches between the peptide
sequences used and the infecting virus.
Our observation that reversion mutations are potentially more
common than CTL escape mutations during the early stages of HIV
infections is broadly in agreement with that of Li et al. (2007) but is at
odds with those of Goonetilleke et al. (2009) and Kearney et al.
(2009). What differentiates ours and the Li et al. study from those of
Goonetilleke et al. and Kearney et al. is that the latter studies
examined sequences sampled pre-seroconversion (Fiebig I/II and III).
We and Li et al. sampled sequences post-seroconversion, in Fiebig V,
VI and beyond. Although CTL escape mutations were only believed to
be detectable 30 or more days after peak viremia (Borrow et al., 1997;
Liu et al., 2006), Goonetilleke et al. (2009) have recently described the
appearance of CTL escape mutations as early 14 days post-infection.
Thus, we may potentially have underestimated the numbers of CTL
escape mutations in viruses which were only sampled a median of
39 days post-infection. This possibly indicates that despite a more
rapid initial accumulation of novel CTL escape mutations during the
ﬁrst weeks of an infection, over the following months the rates at
which successful CTL escape mutations emerge trails off to the point
where their frequency is surpassed by that of reversion mutations.
Nevertheless, our classiﬁcation of reversion and escape mutations
was supported by the fact that some of the sites predicted to be
associated with escape (in Vif and Nef) were located in peptides
reported to be restricted by the HLA alleles of the relevant study
participants, whereas 14/17 evolutionary events at 14 sites we
classiﬁed as being potentially associated with high-frequency
reversion mutations which were not restricted by the HLA alleles
of the relevant study participants. It must be pointed out, however,
that certain HLA-epitope associations may have been missed as it has
previously been shown that CTL responses are poorly predicted in
subtype C sequences due, in part, to lack of detailed characterization
of HLA alleles in African populations (Ngandu et al., 2007). This
result, based on full-length genomes, supports previous studies
based on Gag, Pol and Nef (Brumme et al., 2008; Li et al., 2007),
which suggest that most of the high entropy sites displaying amino
acid frequency differences between viruses sampled in primary and
chronic HIV infections represent defunct escape mutations accumu-
lated in former hosts that had different HLA alleles from the virus'
current hosts.
During early infection many CTL evasion mutations accumulated
within previous hosts revert to their consensus states because these
“wild-type” polymorphisms provide a greater degree of replicative
ﬁtness (Brumme et al., 2008; Martinez-Picado et al., 2006). At the
same time that defunct CTL evasion mutations are reverting, viruses
are forced to escape the immune pressures exerted by the immune
environment of their new hosts. CTL escape during early infections
has been associated with oscillation of amino acids within CTLtargeted epitopes prior to their convergence on more stable states
(Borrow et al., 1997; Delport et al., 2008; Iversen et al., 2006). This
oscillation may either be due to the negative replicative ﬁtness effects
of some CTL evasion mutations or due to some mutations only
providing partial escape from CTL responses due to, for example, their
inﬂuencing epitope processing rather than recognition (Borrow et al.,
1997). By the chronic phase of infections many of these changes may
have reached a degree of equilibrium. It is possible, therefore, that in
our study we have detected different stages of this oscillation process
in the different infection stages. The increased entropy within
targeted CTL epitopes in early infections may be due to amino acid
switching or toggling within targeted epitopes as the viruses try to
balance the survival beneﬁts of CTL escape with the replicative ﬁtness
costs incurred by many CTL evasion mutations (Delport et al., 2008;
Goonetilleke et al., 2009; Iversen et al., 2006).
We provide evidence that the innate potential of particular genetic
variants to mutationally respond to the selective constraints imposed
by new hosts underlie virtually all detectable differences in amino
acid frequency spectra between viruses sampled during primary and
chronic infections. These data provide valuable insights into unique
virological and immunological events during primary infection. We
provide evidence which suggests that during the early stages of HIV
infections adaptation to the immune environment of new hosts is
perhaps secondary to the mutational recovery of replicative ﬁtness
losses incurred during CTL escape in former hosts. Our discovery that
early infections are primarily characterized by reversion mutations
adds to an accumulating body of evidence suggesting the transience of
many immune evasion mutations during global population-wide HIV
evolution. It is becoming increasingly apparent that CTL escape
mutations often have complex evolutionary costs and beneﬁts such
that many are likely to have subtle and difﬁcult to predict inﬂuences
on long-term HIV pathology, epidemiology and evolution. Given that
the mutational accessibility and ﬁtness beneﬁts of reversion muta-
tions that occur during early infections should strongly impact the
broader effects of CTL evasion mutations, our study emphasizes the
importance of studying the evolutionary changes occurring in HIV
during the very earliest stages of infection. Although our data suggest
that the majority of the amino acid frequency spectrum differences
we have observed between viruses sampled during acute and chronic
infections are rationally attributable to evolutionary processes at play
post-transmission, it would nevertheless be of great interest to
determine whether all such signals are generated de novo at the onset
of infections. Evidence of even a small proportion of these signals
having being generated prior to transmission would provide valuable
support for the notion of an evolutionarily relevant “transmission
sieve”.
Materials and methods
Study subjects
Plasma samples were obtained from 20 women who had been
recently infected through heterosexual contact and had been enrolled
within 3 months of infection from prospective cohorts of high-risk
HIV-negative individuals as part of the CAPRISA 002 Acute Infection
study (Table 1) (van Loggerenberg et al., 2008). The time of infection
was estimated as themidpoint between the last seronegative and ﬁrst
seropositive sample or as 14 days if diagnostic tests were antibody
negative but RNA positive. Classiﬁcation of HIV-1 infection stages was
carried out as in (Fiebig et al., 2003) Brieﬂy, individuals classiﬁed with
stage I HIV were HIV RNA positive but p24 antigen negative, those in
stage II were HIV RNA and p24 antigen positive, those in stage III were
antibody-enzyme immuno assay (EIA) positive but Western blot
negative, those in stage IV were antibody EIA positive with an
indeterminate Western blot, those in stage V were Western blot
positive but with no p31 band and those in stage VI wereWestern blot
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therapy naïve.
All samples were collected with informed consent and research
ethics approval was obtained from the Universities of Kwa-Zulu Natal,
Witwatersrand and Cape Town (REC 025/2004).
Assembly of a chronic infection data set
We assembled a reference HIV-1 subtype C chronic infection data
set consisting of 63 publicly available subtype C full-length sequences
(Kiepiela et al., 2004); http://hiv.lanl.gov/components/sequence/
HIV/search/search.html) and an additional 3 full-length sequences
sampled from participants of a sex-worker cohort (Van Damme et al.,
2002). Similar to the sequences from primary infection, the chronic
infection sequences were obtained from heterosexually infected
women with the same ethnic background (Xhosa/Zulu) and from
the same geographic location (Kwa-Zulu Natal, South Africa).
Sequences from participants with AIDS as deﬁned by CD4+ counts
less than 200 cells per μl were excluded. In addition, sequences from
participants with viral loads N200 000 copies/ml were also excluded
to minimize inadvertent inclusion of primary infection sequences in
the chronic infection data set.
Whole genome ampliﬁcation
Full-length genome sequences were generated from a minimum
number of cDNA template molecules in order to both increase the
efﬁciency of full-length genome ampliﬁcation (Rousseau et al., 2006)
and reduce the probability of in vitro recombination during PCR (Fang
et al., 1998; Edmonson and Mullins, 1992). RNA was extracted from
plasma obtained from peripheral blood using the QIAamp® Viral RNA
mini spin kit and protocol (Qiagen, Valencia, CA, USA). Near full-
length HIV-1 genomes were ampliﬁed as a single fragment using a
modiﬁed limiting dilution reverse transcription mediated nested PCR
approach as described previously (Rousseau et al., 2006). Ampliﬁed
full-length genomes were gel puriﬁed and cloned into the XL-TOPO
rapid ligation vector (Invitrogen, GmbH, Karlsruhe, Germany). Cloned
genomes were sequenced in both directions using primer-walking.
Diversity following limiting dilution was assessed using a
heteroduplex tracking assay (HTA). V1V2 env gene fragments were
ampliﬁed from the outer PCR reactions used to generate full-length
genomes and were probed with a radioactively labelled env gene
(V1V2 region) probe generated from the subtype C isolate Du151
using methods described by (Kitrinos et al., 2003).
DNA sequencing
DNA sequencing reactions were performed using the ABI PRISM
Dye Terminator Cycle sequencing kit V3.1 (Applied Biosystems, Foster
City , CA, USA) using both the primers described by which are
speciﬁcally optimized for HIV-1 subtype C sequencing, and those
described by the CAPRISA sequence assembly pipeline tool (www.
tools.caprisa.org) employing the Phred, Phrap and Cross_match
software packages was used to assemble full-length genome
sequences. Assembled sequences and chromatograms were viewed
and edited using Consed.
Phylogenetic analysis
A neighbor-joining tree was constructed in MEGA 4 (Tamura et al.,
2007) for all full genome HIV-1 subtype C sequences from this study
and from the HIV sequence database (total n=421) using amaximum
composite likelihood model with a gamma distribution rate (α=2)
determined using the FindModel tool which is based on MODELTEST
(http://www.hiv.lanl.gov, Posada and Crandall, 1998). The primary
and chronic infection full-length genome data sets were aligned usingClustalW as implemented in BioEdit with manual editing in BioEdit
(Hall, 1999). Full-length genome sequences were split into individual
gene fragments for gene-speciﬁc analyses. A maximum likelihood
phylogenetic tree for the env gene were inferred using PHYML
(Guindon & Gascuel, 2003) as implemented in RDP3.26 (Heath et al.,
2006), using the General Time Reversible nucleotide substitution
model with gamma correction for site-to-site rate variation (α=2)
selected by the FindModel tool (http://www.hiv.lanl.gov; Posada and
Crandall, 1998).
Phylogeny-aware comparison of amino acid mutational spectra
As recombination can seriously confound phylogenetic analyses,
we sought to account for recombination by performing separate
analyses for different alignment partitions as deﬁned by identiﬁed
recombination breakpoints. Recombination breakpoints were identi-
ﬁed in different HIV gene alignments using the RDP (Martin and
Rybicki, 2000), GENECONV (Padidam et al., 1999), BOOTSCAN (Martin
et al., 2005a), MAXCHI , CHIMAERA (Martin and Rybicki, 2000; Martin
et al., 2005b) and SISCAN (Gibbs et al., 2000) methods implemented
in RDP3. Default settings were used throughout and only potential
recombination events detected by two or more of the above methods
(with associate Bonferroni corrected p-valuesb0.05) coupled with
phylogenetic evidence of recombination were considered signiﬁcant.
The gag, pol, env and nef genes were partitioned at breakpoint
positions. Vif, vpr, vpu and tat genes were not detectably recombinant.
Recombination could also not be detected in these genes using the
GARD (Genetic Algorithm for Recombination Detection) method
implemented on the Datamonkey webserver (Pond et al., 2006;
http://www.datamonkey.org). Overlapping reading frames, variable
regions in env as well as insertions or deletions were removed before
genes and partition fragments were translated to amino acids.
Neighbor-joining trees for protein alignments (without bootstrap-
ping) were inferred with MEGA 4 (Tamura et al., 2007) using the
Poisson correction distance model which assumes equal substitution
rates and equal amino acid frequencies. Rev was not analyzed as it is
completely embedded in overlapping reading frames and was
therefore unsuitable for analysis.
For each alignment partition deﬁned by identiﬁed recombination
breakpoints, we inferred the sequences at the ancestral nodes of the
corresponding tree (Edwards and Shields, 2004; Edwards and Shields,
2005) and, for each site, designated the amino acid at the root of the
tree as the ancestral amino acid for that site. Each terminal branch
with a mutation towards the ancestral amino acid was assigned a
score of +1; terminal branches with a mutation from the ancestral
amino acid to any other amino acid were assigned a score of −1 and
terminal branches for which no amino acid replacement was inferred
were assigned a score of 0. We then compared the numbers of−1, 0
and +1 scores in terminal branches leading to sequences sampled
during primary infection to the corresponding numbers from chronic
infection sequences using a two-tailedWilcoxon rank-sum test with a
p-value cut-off of 0.025. We then carried out a permutation test in
order to investigate the impact of multiple hypothesis testing on our
results. We randomly shufﬂed the sample labels (primary/chronic
infection) 1000 times and for each randomization we repeated the
test and evaluated the number of sites with a p-value below the
signiﬁcance threshold.
Site-by-site Shannon entropy estimation
The average entropy was used to estimate the variability at
amino acid sites at each alignment position of the primary and
chronic data sets at signature positions (Yusim et al., 2002; Korber
et al., 1994; http://www.hiv.lanl.gov/tmp/ENTROPY/). HIV-1 sub-
type C sequences available on the HIV sequence database were
used to determine the database frequency of amino acids at
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(n= 413), Nef (n= 586), Rev (n= 457 and n= 562 for exons 1
and 2, respectively), Vif (n= 409), Vpr (n= 401) and Pol (n= 412)
(http://hiv.lanl.gov/components/sequence/HIV/).
Variable loop length and N-linked glycosylation sites (PNGS)
The length (number of amino acids) of env variable loops and
the total number of PNGS were determined with the N-Glycosite
tool on the HIV sequence database (http://www.hiv.lanl.gov/
content/sequence/GLYCOSITE/glycosite.html, Zhang et al., 2004).
Screening for possible CTL epitopes
Motif Scan (a program that uses known HLA-1 restricted CTL
epitope binding motifs to predict HLA-peptide binding sites; http://
www.hiv.lanl.gov/content/immunology/motif_scan/), the CTL epi-
tope database (http://www.hiv.lanl.gov/content/immunology/
ctl_search), the Los Alamos HIV Molecular Immunology Compendium
2006/2007 and the NetMHCpan tool (http://www.cbs.dtu.dk/
services/NetMHCpan/) which use HLA and peptide sequence
information to predict the afﬁnity (nM) of peptide-HLA interactions
(Nielsen et al., 2007) were used to identify putative CTL epitopes
predicted to be restricted by each study participant's particular HLA
alleles.
HLA-I A, B and C typing was carried out at high resolution by
sequencing using the Atria AlleleSeqr (Abbott Diagnostics) and
Assign-SBT 3.5 (Conexio Genomics) kits as described in Chopera
et al. (2008).
We calculated the proportion of immunoreactive peptides with
respect to the complete HIV-1 subtype C proteome by mapping
reported immunoreactive peptides in subtype C infections onto the
viral proteins.
Statistical analyses
The non-parametric Wilcoxon rank-sum test was used to identify
differences between the primary and chronic infection data sets with
respect to both the numbers of N-linked glycosylation sites (PNGs)
and the lengths of the variable loops in env. Differences in entropy
scores between primary and chronic strains at each identiﬁed position
were evaluated using the two-tailed Wilcoxon rank-sum test. These
statistical tests were carried out using GraphPad Prism® 5.0
(GraphPad Software Inc., CA, USA).
The 2×2 chi-square test (http://faculty.vassar.edu/lowry/tab2x2.
html) was used to determine whether or not sites with signiﬁcant
allele frequency spectrum differences between viral isolates from
primary and chronic infections, clustered within immunoreactive
regions of the HIV-1 proteome (Fisher's exact one-tailed T test was
used to measure signiﬁcance).
Nucleotide sequence accession numbers
All near full-length sequences were submitted to GenBank under
accession numbers GQ999972 to GQ999991.
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